Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
ACS Omega ; 9(24): 26066-26074, 2024 Jun 18.
Artigo em Inglês | MEDLINE | ID: mdl-38911785

RESUMO

Pathogen infection represents the greatest challenge to agricultural crop production, resulting in significant economic loss. Conventional pesticides are used to control such infection but can result in antimicrobial resistance and detrimental effects on the plant, environment, and human health. Due to nitric oxide's (NO) endogenous roles in plant immune responses, treatment with exogenous NO represents an attractive nonpesticide approach for eradicating plant pathogens. In this work, the antimicrobial activity of small-molecule NO donors of varying NO-release kinetics was evaluated against Pseudomonas syringae and Botrytis cinerea, two prevalent plant pathogens. Intermediate NO-release kinetics proved to be most effective at eradicating these pathogens in vitro. A selected NO donor (methyl tris diazeniumdiolate; MD3) was capable of treating both bacterial infection of plant leaves and fungal infection of tomato fruit without exerting toxicity to earthworms. Taken together, these results demonstrate the potential for utilizing NO as a broad-spectrum, environmentally safe pesticide and may guide development of other NO donors for such application.

2.
ACS Appl Bio Mater ; 7(6): 3796-3809, 2024 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-38776418

RESUMO

Drug resistance and off-target toxicity are two of the greatest challenges to chemotherapeutic melanoma treatments. Nitric oxide (NO) represents an attractive alternative to conventional therapeutics due to its numerous anticancer properties and low probability of engendering resistance. As NO is highly reactive, macromolecular NO donors are needed for the controlled and targeted delivery of NO for therapeutic applications. Herein, mesoporous silica nanoparticles (MSNs) coated with hyaluronic acid (HA) were developed as a NO delivery system to facilitate controlled delivery to cancer cells through both passive and active targeting via the enhanced permeation and retention effect and directed binding of HA with CD44 receptors, respectively. The aminosilane modification, HA concentration, and HA molecular weight were systematically evaluated to facilitate the MSN coating and NO loading. The hydrodynamic diameter and dispersity of the nanoparticles increased after HA coating due to the hydrophilic nature of HA, with greater increases observed at higher HA molecular weight. Lower starting concentrations of HA and aminosilanes with longer alkyl chains favored more efficient HA coating. Faster NO-release kinetics and lower NO payloads were observed for the HA-coated MSNs relative to uncoated MSNs. However, the localized delivery of NO to cancer cells through the active targeting conferred by HA increased levels of oxidative stress and induced mitochondria-mediated apoptosis in melanoma cells. Cytotoxicity was also evaluated against human dermal fibroblasts, with the use of 6 kDa HA-coated MSNs resulting in the greatest therapeutic indices. Enhanced internalization of HA-coated nanoparticles into melanoma cells versus uncoated nanoparticles was visualized with confocal microscopy and quantified by fluorescence spectroscopy. In total, HA-coated MSNs represent a promising NO delivery system for potential use as a chemotherapeutic for skin melanomas.


Assuntos
Ácido Hialurônico , Teste de Materiais , Nanopartículas , Óxido Nítrico , Tamanho da Partícula , Dióxido de Silício , Ácido Hialurônico/química , Humanos , Dióxido de Silício/química , Nanopartículas/química , Óxido Nítrico/química , Óxido Nítrico/metabolismo , Antineoplásicos/química , Antineoplásicos/farmacologia , Materiais Biocompatíveis/química , Materiais Biocompatíveis/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Sistemas de Liberação de Medicamentos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos
3.
J Fungi (Basel) ; 10(5)2024 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-38786663

RESUMO

Pathogenic fungi are an increasing health threat due to the rise in drug resistance. The limited number of antifungals currently available and growing incidence of multi-drug-resistant fungi has caused rising healthcare costs and a decreased quality of life for patients with fungal infections. Nitric oxide (NO) has previously been shown to act as an antimicrobial agent, albeit with a limited understanding of the effects of the NO-release kinetics against pathogenic fungi. Herein, the antifungal effects of four nitric oxide-releasing small molecules were studied against the pathogenic fungi Candida albicans, Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, to demonstrate the broad-spectrum antifungal activity of NO. A bolus dose of NO was found to eradicate fungi after 24 h, where nitric oxide donors with shorter half-lives achieved antifungal activity at lower concentrations and thus had wider selectivity indexes. Each NO donor was found to cause a severe surface destruction of fungi, and all NO donors exhibited compatibility with currently prescribed antifungals against several different fungi species.

4.
ACS Appl Mater Interfaces ; 15(24): 28907-28921, 2023 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-37285144

RESUMO

In an attempt to address the significant morbidity, mortality, and economic cost associated with tunneled dialysis catheter (TDC) dysfunction, we report the development of nitric oxide-releasing dialysis catheter lock solutions. Catheter lock solutions with a range of NO payloads and release kinetics were prepared using low-molecular-weight N-diazeniumdiolate nitric oxide donors. Nitric oxide released through the catheter surface as a dissolved gas was maintained at therapeutically relevant levels for at least 72 h, supporting clinical translatability (interdialytic period). Slow, sustained NO release from the catheter surface prevented bacterial adhesion in vitro by 88.9 and 99.7% for Pseudomonas aeruginosa and Staphylococcus epidermidis, respectively, outperforming a burst NO-release profile. Furthermore, bacteria adhered to the catheter surface in vitro prior to lock solution use was reduced by 98.7 and 99.2% for P. aeruginosa and S. epidermidis, respectively, when using a slow releasing NO donor, demonstrating both preventative and treatment potential. The adhesion of proteins to the catheter surface, a process often preceding biofilm formation and thrombosis, was also lessened by 60-65% by sustained NO release. In vitro cytotoxicity of catheter extract solutions to mammalian cells was minimal, supporting the non-toxic nature of the NO-releasing lock solutions. The use of the NO-releasing lock solution in an in vivo TDC porcine model demonstrated decreased infection and thrombosis, enhanced catheter functionality, and improved outcome (i.e., likelihood of survival) as a result of catheter use.


Assuntos
Infecções Relacionadas a Cateter , Cateteres Venosos Centrais , Trombose , Animais , Antibacterianos/uso terapêutico , Infecções Relacionadas a Cateter/microbiologia , Soluções para Hemodiálise , Mamíferos , Óxido Nítrico , Diálise Renal , Suínos , Trombose/tratamento farmacológico
5.
ACS Infect Dis ; 9(9): 1730-1741, 2023 09 08.
Artigo em Inglês | MEDLINE | ID: mdl-37566512

RESUMO

Compared to planktonic bacteria, biofilms are notoriously difficult to eradicate due to their inherent protection against the immune response and antimicrobial agents. Inducing biofilm dispersal to improve susceptibility to antibiotics is an attractive therapeutic avenue for eradicating biofilms. Nitric oxide (NO), an endogenous antibacterial agent, has previously been shown to induce biofilm dispersal, but with limited understanding of the effects of NO-release properties. Herein, the antibiofilm effects of five promising NO-releasing biopolymer candidates were studied by assessing dispersal, changes in biofilm viscoelasticity, and increased sensitization to tobramycin after treatment with NO. A threshold level of NO was needed to achieve biofilm dispersal, with longer-releasing systems requiring lower concentrations. The most positively charged NO-release systems (from the presence of primary amines) led to the greatest reduction in viscoelasticity of Pseudomonas aeruginosa biofilms. Co-treatment of tobramycin with the NO-releasing biopolymer greatly decreased the dose of tobramycin required to eradicate tobramycin-susceptible and -resistant biofilms in both cellular and tissue models.


Assuntos
Antibacterianos , Anti-Infecciosos , Antibacterianos/farmacologia , Óxido Nítrico/farmacologia , Tobramicina/farmacologia , Anti-Infecciosos/farmacologia , Biofilmes
6.
ACS Biomater Sci Eng ; 8(6): 2537-2552, 2022 06 13.
Artigo em Inglês | MEDLINE | ID: mdl-35580341

RESUMO

Two glycosaminoglycan (GAG) biopolymers, hyaluronic acid (HA) and chondroitin sulfate (CS), were chemically modified via carbodiimide chemistry to facilitate the loading and release of nitric oxide (NO) to develop a multi-action wound healing agent. The resulting NO-releasing GAGs released 0.2-0.9 µmol NO mg-1 GAG into simulated wound fluid with NO-release half-lives ranging from 20 to 110 min. GAGs containing alkylamines with terminal primary amines and displaying intermediate NO-release kinetics exhibited potent, broad spectrum bactericidal action against three strains each of Pseudomonas aeruginosa and Staphylococcus aureus ranging in antibiotic resistance profile. NO loading of the GAGs was also found to decrease murine TLR4 activation, suggesting that the therapeutic exhibits anti-inflammatory mechanisms. In vitro adhesion and proliferation assays utilizing human dermal fibroblasts and human epidermal keratinocytes displayed differences as a function of the GAG backbone, alkylamine identity, and NO-release properties. In combination with antibacterial properties, the adhesion and proliferation profiles of the GAG derivatives enabled the selection of the most promising wound healing candidates for subsequent in vivo studies. A P. aeruginosa-infected murine wound model revealed the benefits of CS over HA as a pro-wound healing NO donor scaffold, with benefits of accelerated wound closure and decreased bacterial burden attributable to both active NO release and the biopolymer backbone.


Assuntos
Glicosaminoglicanos , Óxido Nítrico , Animais , Fibroblastos , Glicosaminoglicanos/farmacologia , Glicosaminoglicanos/uso terapêutico , Humanos , Ácido Hialurônico/farmacologia , Camundongos , Óxido Nítrico/química , Cicatrização/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA